Cardionyx Heart Science

Smart Autonomic Tone Control

Health Tech & Life Sciences
Active
Seed Tel Aviv-Yafo, Israel Founded 2020
Last updated 2026-06-18
Total raised
$700K
Last: 2023-08
Stage
Seed
Founded
2020
Headcount
2
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Cardionyx is developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, through a minimally invasive approach. Cardionyx stands at the forefront of medical innovation, poised to address the critical clinical needs of Heart Failure (HF) patients with reduced ejection fraction (HFrEF) through its groundbreaking approach.

With a relentless focus on improving the lives of patients facing diminished life expectancy, frequent hospitalizations, and compromised quality of life (QOL), Cardionyx is developing a first-of-its-kind trans-vessel active implant designed to stimulate electricly baroreceptors, offering a potential game-changer in HF treatment. Unlike conventional therapies, which often leave a significant portion of patients ineligible or poorly managed, Cardionyx redefines the possibilities of intervention. At the core of this innovation lies an implant that leverages venous catheterization for implantation, ensuring a safer and quicker procedure which fits the clinical profile of this patient population.

Another aspect that truly sets Cardionyx apart is its ability to provide personalized therapy coupled with real-time hemodynamic monitoring, allowing for the dynamic regulation of parasympathetic tone. This unique feature enables adjustable upregulation according to the patient's evolving hemodynamics, maximizing efficacy while minimizing adverse events and reducing the likelihood of baroreceptor desensitization.

Funding history · 1 round · $700K total

2023-08
$700K

Q&A

What is Cardionyx Heart Science developing?
Cardionyx Heart Science is developing a first-of-its-kind trans-vessel active implant designed to electrically stimulate baroreceptors for Heart Failure (HF) patients with reduced ejection fraction (HFrEF).
When was Cardionyx Heart Science founded?
Cardionyx Heart Science was founded in November 2020.
What is the primary sector of Cardionyx Heart Science?
The primary sector of Cardionyx Heart Science is Health Tech & Life Sciences.
How much funding has Cardionyx Heart Science raised in total?
Cardionyx Heart Science has raised a total of $700,000.
When did Cardionyx Heart Science complete its last funding round?
Cardionyx Heart Science completed its last funding round in August 2023, raising $700,000.
What is the current employee count for Cardionyx Heart Science?
Cardionyx Heart Science has 1-10 employees.
What is the key innovation of Cardionyx Heart Science's implant?
The implant from Cardionyx Heart Science provides personalized therapy coupled with real-time hemodynamic monitoring, allowing for dynamic regulation of parasympathetic tone.
Does Cardionyx Heart Science hold any patents?
Yes, Cardionyx Heart Science holds 1 patent.

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B

Highlights

1 PatentsVerified

Tags

pumpsheart-failurechronic-patientsnon-invasivemedical-devicescardiovascularmedical-technologieshealthcare-providerssurgerypatientsartificial-intelligence
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)